Corbion and MedinCell form joint venture to supply resorbable polymers for controlled drug release

Corbion and MedinCell are establishing a 50/50 joint venture for the supply of PEG (polyethyleneglycol) and PLA (polylactic acid) based co-polymers in the field of controlled release drug delivery.

The joint venture, CM Biomaterials, will sell the PEG / PLA co-polymers to MedinCell partners who license the MedinCell technology (BEPO™). Manufacturing of the polymers will take place in Corbion’s medical biomaterials plants in the US and the Netherlands, while development and licensing of the technology remain the exclusive responsibility of MedinCell. CM Biomaterials will be established in the Netherlands.

Marco Bootz, SVP Biochemicals, Corbion: “Corbion and MedinCell have been in a joint development program since 2010, to optimize the manufacturing of PEG/PLA polymers for drug delivery. This cooperation has now successfully developed into a joint venture for the supply of PEG/PLA polymers. In this joint venture, Corbion will be responsible for manufacturing the polymers and with our complementary expertise in the field of polymers we will together develop the optimal polymers for MedinCell’s applications. Corbion is the global leader in the field of resorbable polymers for drug delivery and medical devices. This new technology will further enhance our position in medical biomaterials”.

Christophe Douat, CEO of MedinCell: “The creation of CM Biomaterials validates our balanced network company model that aims to gather leaders in many fields to create best-in-class medicines for Global Health. Based on a complementary partnership, CM Biomaterials will best serve BEPO™ partners and secure the quality of the polymers used for all BEPO™ applications.”

Based on a combination of co-polymers, solvent and API (Active Pharmaceutical Ingredient), the BEPO™ technology can provide a controlled release of drug for days, weeks or months from a fully biodegradable depot that forms after subcutaneous injection or local delivery of the formulated API. As a game-changing technology, BEPO™ combines many advantages compared to alternative drug delivery technologies, including improved patient compliance, efficacy and tolerability, as well as, versatility, development speed and lower manufacturing costs.

Corbion: biobased solutions, designed by science, powered by nature, and delivered through dedication.

Corbion is the global market leader in lactic acid, lactic acid derivatives and lactides, and a leading company in functional blends containing enzymes, emulsifiers, minerals and vitamins. The company delivers high performance biobased products made from renewable resources and applied in global markets such as bakery, meat, pharmaceuticals and medical devices, home and personal care, packaging, automotive, coatings and adhesives. Its products have a differentiating functionality in all kinds of consumer products worldwide. In 2014, Corbion generated annual sales of €770.1 million and had a workforce of 1,893 employees. Corbion is listed on NYSE Euronext Amsterdam. For more information:


Share this on